U.S., Aug. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07744802) titled 'Evaluate the Effect of Vimseltinib on P-glycoprotein (P-gp) Inhibition in Healthy Male Participants' on July 30.
Brief Summary: The main purpose of this study is to determine the effect of vimseltinib on pharmacokinetics of P-glycoprotein (P-gp) substrate (dabigatran) in healthy male participants. This study will last approximately 21 days.
Study Start Date: Aug., 2026
Study Type: INTERVENTIONAL
Condition:
Healthy Male Participants
Intervention:
DRUG: Vimseltinib
Administered orally
DRUG: Dabigatran
Administered orally
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Deciphera Pharmaceuticals, LLC
Published by HT Digital C...